Individuals with type 2 diabetes and painful symptomatic knee osteoarthritis are less likely to achieve target glycemic ...
Vixarelimab showed rapid, sustained itch reduction and good safety in prurigo nodularis. Learn more about the study and ...
A phase 3 trial shows that apremilast, an oral phosphodiesterase 4 inhibitor, improves symptoms, disease severity, and ...
Nemolizumab rapidly relieves itch and sleep disturbance among patients with moderate-to-severe atopic dermatitis (AD) and ...
The CCS board offered Superintendent Angela Chapman pointed feedback in her evaluation, saying her performance has ...
Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous malformations.
Vixarelimab showed significant symptom relief and disease progression reduction in prurigo nodularis compared with placebo across all doses. A phase 2b trial found vixarelimab rapidly reduced itch and ...
Nektar Therapeutics reported Phase 2b alopecia areata data showing hair regrowth trends, narrowly missing significance before eligibility adjustments.
Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...
IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis. 3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in ...
Vixarelimab led to rapid, dose-dependent reductions in itch severity compared with placebo, with more than 50% decreases in WI-NRS scores at week 16 in the high- and mid-dose groups, and meaningful ...
Researchers have found in a new study that Nemolizumab demonstrated rapid and meaningful symptom relief in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback